Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04167345 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype
A Phase 2 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Terminated
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT04167345 is a Phase 2 study that was terminated before completion, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 48 participants.
The verdict
NCT04167345, a Phase 2 study, was terminated before completion, sponsored by Vertex Pharmaceuticals Incorporated.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-814 in PiZZ subjects.
Interventions
- DRUG Placebo
- DRUG VX-814
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2020-01-13 |
| Est. Completion | 2020-11-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04167345
The ClinicalTrials.gov registry entry for NCT04167345 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04167345 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04167345 about?
NCT04167345 is a clinical study titled "Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype". This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-814 in PiZZ subjects.
What is the current status of trial NCT04167345?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2020-01-13. Estimated completion is 2020-11-14.
What interventions are being tested in trial NCT04167345?
The interventions under investigation include: Placebo (DRUG), VX-814 (DRUG).
Who is sponsoring clinical trial NCT04167345?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.